Application of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography imaging in recurrent anastomotic tumors after surgery in digestive tract tumors.

Autor:	Ge DF; Department of Cardiothoracic Surgery, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China., Ren H; Department of Cardiothoracic Surgery, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China., Yang ZC; Department of Cardiothoracic Surgery, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China., Zhao SX; Department of Cardiothoracic Surgery, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China., Cheng ZT; Department of Cardiothoracic Surgery, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China., Wu DD; Department of Gastrointestinal Surgery, Shanghai Sixth People's Hospital, Shanghai 250063, China., Zhang B; Department of Cardiothoracic Surgery, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China. 13901599064@163.com.
Jazyk:	angličtina
Zdroj:	World journal of gastrointestinal surgery [World J Gastrointest Surg] 2024 Aug 27; Vol. 16 (8), pp. 2474-2483.
DOI:	10.4240/wjgs.v16.i8.2474
Abstrakt:	Background: This study was to investigate the application value of whole-body dynamic 18 F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging in recurrent anastomotic tumors of digestive tract after gastric and esophageal cancer surgery. Postoperative patients with gastric and esophageal cancer have a high risk of tumor recurrence, and traditional imaging methods have certain limitations in early detection of recurrent tumors. Whole-body dynamic 18 F-FDG PET/CT imaging, due to its high sensitivity and specificity, can provide comprehensive information on tumor metabolic activity, which is expected to improve the early diagnosis rate of postoperative recurrent tumors, and provide an important reference for clinical treatment decision-making. Aim: To investigate the clinical value of whole-body dynamic 18 F-FDG PET/CT imaging in differentiating anastomotic recurrence and inflammation after the operation of upper digestive tract tumors. Methods: A retrospective analysis was performed on 53 patients with upper digestive tract tumors after operation and systemic dynamic 18 F-FDG PET/CT imaging indicating abnormal FDG uptake by anastomosis, including 29 cases of gastric cancer and 24 cases of esophageal cancer. According to the follow-up results of gastroscopy and other imaging examinations before and after PET/CT examination, the patients were divided into an anastomotic recurrence group and anastomotic inflammation group. Patlak multi-parameter analysis software was used to obtain the metabolic rate (MRFDG), volume of distribution maximum (DVmax) of anastomotic lesions, and MRmean and DVmean of normal liver tissue. The lesion/background ratio (LBR) was calculated by dividing the MRFDG and DVmax of the anastomotic lesion by the MRmean and DVmean of the normal liver tissue, respectively, to obtain LBR-MRFDG and LBR-DVmax. An independent sample t test was used for statistical analysis, and a receiver operating characteristic curve was used to analyze the differential diagnostic efficacy of each parameter for anastomotic recurrence and inflammation. Results: The dynamic 18 F-FDG PET/CT imaging parameters MRFDG, DVmax, LBR-MRFDG, and LBR-DVmax of postoperative anastomotic lesions in gastric cancer and esophageal cancer showed statistically significant differences between the recurrence group and the inflammatory group ( P < 0.05). The parameter LBR-MRFDG showed good diagnostic efficacy in differentiating anastomotic inflammation from recurrent lesions. In the gastric cancer group, the area under the curve (AUC) value was 0.935 (0.778, 0.993) when the threshold was 1.83, and in the esophageal cancer group, the AUC value was 1. When 86 is the threshold, the AUC value is 0.927 (0.743, 0.993). Conclusion: Whole-body dynamic 18 F-FDG PET/CT imaging can accurately differentiate the diagnosis of postoperative anastomotic recurrence and inflammation of gastric cancer and esophageal cancer and has the potential to be an effective monitoring method for patients with upper digestive tract tumors after surgical treatment. Competing Interests: Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article. (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu